26929-63-5Relevant articles and documents
Asymmetric Disulfanylbenzamides as Irreversible and Selective Inhibitors of Staphylococcus aureus Sortase A
Barthels, Fabian,Bierlmeier, Jan,Distler, Ute,Hammerschmidt, Stefan,Konh?user, Matthias,Marciniak, Tessa,Marincola, Gabriella,Schirmeister, Tanja,Schwarzer, Dirk,Tenzer, Stefan,Wich, Peter R.,Ziebuhr, Wilma
supporting information, (2020/04/22)
Staphylococcus aureus is one of the most frequent causes of nosocomial and community-acquired infections, with drug-resistant strains being responsible for tens of thousands of deaths per year. S. aureus sortase A inhibitors are designed to interfere with
Conformationally constrained peptides and semipeptides derived from RGD as potent inhibitors of the platelet fibrinogen receptor and platelet aggregation
Ali,Bennett,Calvo,Elliott,Hwang,Ku,Lago,Nichols,Romoff,Shah,Vasko,Wong,Yellin,Yuan,Samanen
, p. 769 - 780 (2007/10/02)
Structure-activity studies have been pursued on cyclo-S,S-[Ac-Cys-(N(α)- Me)Arg-Gly-Asp-Pen]-NH2, 2 (SK and F 106760), a potent inhibitor of platelet aggregation, in an effort to improve potency and affinity for the GPIIb/IIIa receptor. Modific